|  Help  |  About  |  Contact Us

Publication : A selective thyroid hormone β receptor agonist enhances human and rodent oligodendrocyte differentiation.

First Author  Baxi EG Year  2014
Journal  Glia Volume  62
Issue  9 Pages  1513-29
PubMed ID  24863526 Mgi Jnum  J:211340
Mgi Id  MGI:5574526 Doi  10.1002/glia.22697
Citation  Baxi EG, et al. (2014) A selective thyroid hormone beta receptor agonist enhances human and rodent oligodendrocyte differentiation. Glia 62(9):1513-29
abstractText  Nerve conduction within the mammalian central nervous system is made efficient by oligodendrocyte-derived myelin. Historically, thyroid hormones have a well described role in regulating oligodendrocyte differentiation and myelination during development; however, it remains unclear which thyroid hormone receptors are required to drive these effects. This is a question with clinical relevance since nonspecific thyroid receptor stimulation can produce deleterious side-effects. Here we report that GC-1, a thyromimetic with selective thyroid receptor beta action and a potentially limited side-effect profile, promotes in vitro oligodendrogenesis from both rodent and human oligodendrocyte progenitor cells. In addition, we used in vivo genetic fate tracing of oligodendrocyte progenitor cells via PDGFalphaR-CreER;Rosa26-eYFP double-transgenic mice to examine the effect of GC-1 on cellular fate and find that treatment with GC-1 during developmental myelination promotes oligodendrogenesis within the corpus callosum, occipital cortex and optic nerve. GC-1 was also observed to enhance the expression of the myelin proteins MBP, CNP and MAG within the same regions. These results indicate that a beta receptor selective thyromimetic can enhance oligodendrocyte differentiation in vitro and during developmental myelination in vivo and warrants further study as a therapeutic agent for demyelinating models. GLIA 2014;62:1513-1529.
Quick Links:
Quick Links:


Publication --> Expression annotations



6 Bio Entities

Trail: Publication

0 Expression